Key points from this report:
- We continue to recommend overweighting Hong Kong Health Care. See our October 21 report here.
- Hong Kong’s Health Care sector has been consolidating for two months and is now beginning to show technical improvement. The industry backdrop remains favorable.
- Focus List is overweight Health Care, with seven out of 18 Focus List stocks.
- Hong Kong Health Care Focus List stocks have RS Ratings between 62 and 95.
- Focus List ideas:
- Extended leaders: Wuxi Biologics ( WXBO.HK; 2269 HK ), Wuxi Apptec ( WUXA.HK; 2359 HK ).
- Newly actionable: Shandong Weigao ( SDW.HK; 1066 HK ).
- Setting up: Hansoh Pharma ( HANP.HK; 3692 HK ), Jinxin Fertility ( JIFG.HK; 1951 HK ), Viva Biotech ( VIVB.HK; 1873 HK ).
- Basing: Yichang Hec Changjiang Pharma ( YHEC.HK; 1558 HK ).
